Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab fixed-dose safety study in advanced solid malignancies
2016-005068-33Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of durvalumab and tremelimumab in Nonhematologic neoplasms and urinary tract cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Adverse events of special interest outcome measures. Started May 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
Nonhematologic neoplasmsurinary tract cancer
Beyond the preview
Go deeper on 2016-005068-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005068-33.